Next Article in Journal
Publisher’s Note: A New Chapter for Advances in Respiratory Medicine—Continued Publication by MDPI
Previous Article in Journal
Should a Prescription Database Be Used to Search Uncontrolled Severe Asthmatics?
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
ARM
Volume 90
Issue 3
10.5603/ARM.a2022.0034
arm-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
Advances in Respiratory Medicine is published by MDPI from Volume 90 Issue 4 (2022). Previous articles were published by another publisher in Open Access under a CC-BY (or CC-BY-NC-ND) licence, and they are hosted by MDPI on mdpi.com as a courtesy and upon agreement with Via Medica.
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Letter

Ad Hoc Afatinib in an Eldery Lung Cancer Patient with EGFR Exon 19 Deletion L747-A750>P

by
Annalisa Guida
1,
Valentina Tassi
2,*,
Francesco Facchinetti
3,
Giovanni Marchetti
4,
Cecilia Caprera
4,
Mark Ragusa
2,
Marcello Tiseo
5,6 and
Sergio Bracarda
1
1
Medical Oncology, Azienda Ospedaliera Santa Maria, Terni, Italy
2
Thoracic Surgery Unit, Azienda Ospedaliera Santa Maria, via Tristano di Joannucci, 05100 Terni, Italy
3
Université Paris-Saclay, Institut Gustave Roussy, Inserm, Biomarqueurs prédictifs et nouvelles stratégies thérapeutiques en oncologie, Villejuif, France
4
Division of Pathology, Azienda Ospedaliera Santa Maria, Terni, Italy
5
Department of Medicine and Surgery, University Hospital of Parma, Parma, Italy
6
Medical Oncology Unit, University Hospital of Parma, Parma, Italy
*
Author to whom correspondence should be addressed.
Adv. Respir. Med. 2022, 90(3), 234-235; https://doi.org/10.5603/ARM.a2022.0034
Submission received: 26 April 2022 / Revised: 7 May 2022 / Accepted: 7 May 2022 / Published: 17 May 2022

Excerpt

Note: In lieu of an abstract, this is an excerpt from the first page.

Approximately 10–20% of patients with non–small-cell lung cancer (NSCLC) harbor an epidermal growth factor receptor (EGFR) [...]

Share and Cite

MDPI and ACS Style

Guida, A.; Tassi, V.; Facchinetti, F.; Marchetti, G.; Caprera, C.; Ragusa, M.; Tiseo, M.; Bracarda, S. Ad Hoc Afatinib in an Eldery Lung Cancer Patient with EGFR Exon 19 Deletion L747-A750>P. Adv. Respir. Med. 2022, 90, 234-235. https://doi.org/10.5603/ARM.a2022.0034

AMA Style

Guida A, Tassi V, Facchinetti F, Marchetti G, Caprera C, Ragusa M, Tiseo M, Bracarda S. Ad Hoc Afatinib in an Eldery Lung Cancer Patient with EGFR Exon 19 Deletion L747-A750>P. Advances in Respiratory Medicine. 2022; 90(3):234-235. https://doi.org/10.5603/ARM.a2022.0034

Chicago/Turabian Style

Guida, Annalisa, Valentina Tassi, Francesco Facchinetti, Giovanni Marchetti, Cecilia Caprera, Mark Ragusa, Marcello Tiseo, and Sergio Bracarda. 2022. "Ad Hoc Afatinib in an Eldery Lung Cancer Patient with EGFR Exon 19 Deletion L747-A750>P" Advances in Respiratory Medicine 90, no. 3: 234-235. https://doi.org/10.5603/ARM.a2022.0034

Article Metrics

Back to TopTop